Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AN2 Therapeutics, Inc.
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights
August 13, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease
August 08, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
May 14, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
March 28, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
February 12, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
January 30, 2024
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
November 09, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 06, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
October 18, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
October 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
September 26, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
September 13, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
August 15, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
August 10, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Present at Jefferies Healthcare Conference
May 25, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
May 11, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
May 01, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
March 29, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Participate in Upcoming Investor Conferences
February 28, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
January 31, 2023
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 09, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ANTX
AN2 Therapeutics to Present at Upcoming Investor Conferences
November 02, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ANTX
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
October 19, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ANTX
AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease
October 06, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ANTX
NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million
September 29, 2022
From
AN2 Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ANTX
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
May 09, 2022
From
AN2 Therapeutics, Inc.
Via
Business Wire
Tickers
ANTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright